Patents Assigned to Amgen
  • FORMULATIONS
    Publication number: 20190345238
    Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.
    Type: Application
    Filed: May 22, 2019
    Publication date: November 14, 2019
    Applicant: AMGEN INC.
    Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
  • Human PAC1 antibodies
    Patent number: 10472417
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Bicyclic ketone sulfonamide compounds
    Patent number: 10472356
    Abstract: The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Benjamin Charles Milgram, Thomas Dineen, John Stellwagen, Angel Guzman-Perez, Alessandro Boezio, Issac E. Marx
  • BCMA antigen binding proteins
    Patent number: 10465009
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 5, 2019
    Assignee: Amgen Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko, Zhulun Wang, Athena Sudom
  • Growth Differentiation Factor 15 (GDF-15) Polypeptides
    Publication number: 20190315822
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20190309306
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: August 25, 2017
    Publication date: October 10, 2019
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • ERENUMAB COMPOSITIONS AND USES THEREOF
    Publication number: 20190300617
    Abstract: The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Applicant: AMGEN INC.
    Inventors: Kenneth LAWSON, Noel RIEDER, Suminda HAPUARACHCHI, Jose Gregorio RAMIREZ
  • TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20190300507
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, I or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 3, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Alan C. CHENG, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Vatee PATTAROPONG, Gayathri SWAMINATH, Charles KREIMAN, David C. MOEBIUS, Ankit SHARMA
  • ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20190290647
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN, Ankit SHARMA
  • CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20190290648
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, David J. KOPECKY, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN
  • Heterocyclic compounds and their uses
    Patent number: 10421726
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Mingda Bi, Robert Kuehl
  • Proteins specific for BAFF and B7RP1
    Patent number: 10421824
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
  • Proteins specific for BAFF and B7RP1 and uses thereof
    Patent number: 10421823
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
  • Methods for increasing mannose content of recombinant proteins
    Patent number: 10421987
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: September 24, 2019
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20190284173
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 19, 2019
    Applicant: AMGEN INC.
    Inventors: Ning CHEN, Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Charles KREIMAN
  • TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20190275008
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 12, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew BROWN, Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, James S. HARVEY, Julie Anne HEATH, Lars V. HEUMANN, Jonathan HOUZE, Frank KAYSER, Aarif Yusuf KHAKOO, David j. KOPECKY, Su-Jen LAI, Zhihua MA, Julio C. MEDINA, Jeffrey T. MIHALIC, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Malgorzata WANSKA, Wen-Chen YEH
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
    Publication number: 20190276546
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 12, 2019
    Applicant: AMGEN INC.
    Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, JR., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
  • Method for preparing AMG 416
    Patent number: 10407464
    Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 10, 2019
    Assignee: Amgen Inc.
    Inventors: Jeroen Bezemer, Ying Chen, Richard Crockett, Kevin Crossley, Sheng Cui, Liang Huang, Sian Jones, Asher Lower, Krishnakumar Ranganathan
  • Variant activin receptor
    Patent number: 10407487
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Autoinjector
    Patent number: D864378
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: October 22, 2019
    Assignee: AMGEN INC.
    Inventors: Sahba Tafazoli, Emily Card Razaqi, Valerie M. Fenster, Stephanie Toy, Scott R. Gibson, Denise Meyer, Erik Timpers, Catherine Arboleda Tamura, Peter T. So, Ravi Sawhney, Lance Hussey, Harnish Jani, Kurt Botsai, Young Bang, Gregory VanderPol, Shushuo Wu, Cathy Tran, Noureddine Malaeb